Opinion|Videos|November 8, 2024
Overcoming Unmet Needs in Treating mCSPC: ADT Monotherapy vs Multimodal Approaches
Key Takeaways
- mCSPC treatment requires personalized approaches, considering disease burden, patient comorbidities, and genetic profiles to optimize outcomes.
- There is a significant need for more effective therapeutic strategies to improve patient outcomes in mCSPC.
Panelists discuss how some of the most critical challenges and unmet needs in the treatment and management of metastatic castration-sensitive prostate cancer (mCSPC) include the effectiveness of monotherapy, the need for better risk stratification, and the integration of novel therapies to improve patient outcomes.
Advertisement
Episodes in this series
Video content above is prompted by the following:
What are some of the most critical challenges and unmet needs in the treatment and management of mCSPC?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves first-line Zenflow system for the treatment of BPH
2
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
3
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC
4
EMA recommends conditional approval of Anktiva in BCG-unresponsive NMIBC
5
